Agreement

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38

Genmab

Drug Development

Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cance

Janssen Pharmaceutical Companies

FDA Approval

U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen

Janssen Pharmaceutical Companies

Phase 3

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

Janssen Pharmaceutical Companies

Depression

New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans

Janssen Pharmaceutical Companies

Clinical Data

Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Janssen Pharmaceutical Companies

New Drug Application

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer

Janssen Pharmaceutical Companies

Study Results

Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1

Janssen Pharmaceutical Companies

Regulatory

Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen

Janssen Pharmaceutical Companies

Positive Opinion

Janssen Receives Positive CHMP Opinion for Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma

Janssen Pharmaceutical Companies

FDA Approval

Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

Janssen Pharmaceutical Companies

Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma

Janssen Pharmaceutical Companies

Real-World Study

New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli

Janssen Pharmaceutical Companies

Commission Approval

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

Janssen Pharmaceutical Companies

Data Presentation

Janssen to Present Data in Treatment-Resistant Mental Ilnesses

Janssen Pharmaceutical Companies

Acquisition

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

Janssen Pharmaceutical Companies

Study

Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes

Janssen Pharmaceutical Companies

Cardiovascular

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

Janssen Pharmaceutical Companies

Biologics

Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management

Spherix Global Insights